Skip to main content
Clinical Trials/NCT02593591
NCT02593591
Completed
Not Applicable

Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.

Samsung Medical Center1 site in 1 country40 target enrollmentNovember 6, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Colorectal Cancer
Sponsor
Samsung Medical Center
Enrollment
40
Locations
1
Primary Endpoint
Response rate
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly. The genome analysis needs systematic infra and database based on personal genetic information. Therefore, a big data of genome-clinical information is important.

To determine the feasibility of the use of tumor's molecular profiling and targeted therapies in the treatment of advanced cancer and to determine the clinical outcome(Response rate,PFS, duration of response and overall survival )of patients with advanced cancer, the investigators are going to take a tumor tissue of patients and process molecular profiling and receive molecular profile directed treatments.

Registry
clinicaltrials.gov
Start Date
November 6, 2015
End Date
July 31, 2018
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Seung tae Kim

MD,PhD,Division of hematology-oncology,Department of medicine

Samsung Medical Center

Eligibility Criteria

Inclusion Criteria

  • Subject is at least 19 years of age.
  • Subject has a histologically or cytologically confirmed diagnosis of Colorectal cancer.
  • Prior treatment with anti-PDL1 antibody or immune check point inhibitor or ramucirumab therapy in the First-line or maintenance setting is allowed
  • They must have refractory or progressive disease for which there is no further curative therapy available.
  • Be willing to provide fresh tissue for biomarker analysis, and, based on the adequacy of the tissue sample quality for assessment of biomarker status.
  • Must have a life expectancy of 3 months or more
  • Written and voluntary informed consent understood, signed and dated.

Exclusion Criteria

  • Patients who do not have enough tissue for acquisition

Outcomes

Primary Outcomes

Response rate

Time Frame: 1 year

Secondary Outcomes

  • Progression Free Survival(1 year)
  • Duration of response(1 year)
  • overall survival(1 year)

Study Sites (1)

Loading locations...

Similar Trials